Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Heart Rhythm. 2018 Jul;15(7):1017-1022. doi: 10.1016/j.hrthm.2018.02.032. Epub 2018 Mar 2.
Cardiac resynchronization therapy (CRT) is an effective treatment for selected patients with heart failure, but it can be limited by the inability to place the left ventricular (LV) lead via the coronary sinus.
The purpose of this study was to develop an alternative approach, placing the LV lead endocardially via an interventricular septal puncture, and to assess the feasibility and safety of this technique.
All patients were anticoagulated with warfarin (international normalized ratio 2.5-3.5). A superior approach ventricular transseptal puncture using radiofrequency energy was performed. An active fixation pacing lead was delivered to the mapped site of latest electrical activation on the endocardial LV.
Twenty patients were recruited, 15 with failed transvenous LV lead placement and 5 nonresponders to CRT. Mean (± SD) age was 67 ± 12, with 80% male, QRS duration 157 ± 14 ms, ischemic etiology 45%, New York Heart Association functional class 2.9 ± 0.4, and LV ejection fraction 28% ± 7%. The procedure was successful in all, with no serious complications. Clinical composite score improved at 6 months in 65% and worsened in 35%. LV ejection fraction improved >5% in 88%, from 28% ± 7% to 41% ± 9%. Six-minute walking distance improved >10% in 64%, from 248 ± 125 m to 316 ± 109 m. One patient suffered a lacunar ischemic stroke after 5 months with partial neurological recovery, associated with labile international normalized ratios. After 2.0 ± 1.0 years of follow-up, 3 patients died (2 pneumonia, 1 heart failure), and 2 patients suffered transient ischemic attacks.
LV endocardial pacing via interventricular septal puncture in patients for whom standard CRT is not possible is similarly effective and durable, with significant but potentially acceptable risks.
心脏再同步治疗(CRT)是一种治疗心力衰竭的有效方法,但由于无法将左心室(LV)导线通过冠状窦放置,因此存在局限性。
本研究旨在开发一种替代方法,通过室间隔穿刺将 LV 导线放置在心内膜上,并评估该技术的可行性和安全性。
所有患者均接受华法林抗凝治疗(国际标准化比值 2.5-3.5)。采用射频能量进行经上腔静脉的室间隔穿刺。将主动固定起搏导线递送至心内膜 LV 上最晚电激活的标测部位。
共纳入 20 例患者,其中 15 例为经静脉 LV 导线放置失败,5 例为 CRT 无反应者。平均(±SD)年龄为 67±12 岁,80%为男性,QRS 时限为 157±14ms,缺血性病因占 45%,纽约心脏协会功能分级为 2.9±0.4,左心室射血分数为 28%±7%。所有患者均成功完成手术,无严重并发症。6 个月时临床综合评分改善者占 65%,恶化者占 35%。88%的患者左心室射血分数提高>5%,从 28%±7%提高至 41%±9%。6 分钟步行距离提高>10%者占 64%,从 248±125m 提高至 316±109m。1 例患者在 5 个月时发生腔隙性脑梗死,伴部分神经功能恢复,与不稳定的国际标准化比值相关。随访 2.0±1.0 年后,3 例患者死亡(2 例肺炎,1 例心力衰竭),2 例患者发生短暂性脑缺血发作。
对于无法进行标准 CRT 的患者,通过室间隔穿刺将 LV 导线放置在心内膜上同样有效且持久,但存在显著但可接受的风险。